Royalty Pharma
Biotechnology, 110 E 59th St Fl 33, New York, 10022, United States, 11-50 Employees
Phone Number: 12*********
Who is ROYALTY PHARMA
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators...
Read More
-
Headquarters: 110 E 59th St Fl 33, New York, New York, 10022, United States
-
Date Founded: 1996
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from ROYALTY PHARMA
Royalty Pharma Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Royalty Pharma
Answer: Royalty Pharma's headquarters are located at 110 E 59th St Fl 33, New York, 10022, United States
Answer: Royalty Pharma's phone number is 12*********
Answer: Royalty Pharma's official website is https://royaltypharma.com
Answer: Royalty Pharma's revenue is $5 Million to $10 Million
Answer: Royalty Pharma's SIC: 2834
Answer: Royalty Pharma's NAICS: 325412
Answer: Royalty Pharma has 11-50 employees
Answer: Royalty Pharma is in Biotechnology
Answer: Royalty Pharma contact info: Phone number: 12********* Website: https://royaltypharma.com
Answer: Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industrys leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharmas current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnsons Imbruvica, Astellas and Pfizers Xtandi, Biogens Tysabri, Johnson & Johnsons Tremfya, Gileads Trodelvy, Mercks Januvia, Novartis Promacta, Vertexs Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month